

Equity issue	Datum	Capital Raised	# new shares	Offer price	Days Between
	31/12/2010		13.185.614		
The net proceeds of the private placement will increase MDxHealth's financial flexibility. They will be used to accelerate product development in line with the new business strategy and <a href="#">to set up a CLIA laboratory and hire a sales and marketing team in the US.</a>	05/04/2011	8.155.070 €	5.436.713	1,50 €	
On July 4, 2012, the company raised €10 million in new equity funding via a private placement.	04/04/2012	9.992.114 €	6.891.113	1,45 €	365d
The net proceeds of the private placement will be used to <a href="#">support and scale-up the Company's U.S.-based CLIA-registered commercial laboratory</a> , its US-based sales and marketing efforts, European and global commercial efforts for its Clinical Molecular Diagnostics (ClinicalMDx) and Pharmaco Molecular Diagnostics (PharmacoMDx) solutions and services to clinicians and pharmaceutical customers, and to accelerate proprietary product development.	25/06/2013	18.123.598 €	8.797.863	2,06 €	447d
these funds allow us to <a href="#">support and scale-up MDxHealth's U.S.-based managed care and related healthcare reimbursement efforts</a> , together with its sales and marketing efforts. In addition, it will allow us to accelerate product development and finance general corporate purposes."	05/11/2014	12.330.000 €	3.425.000	3,60 €	498d
these funds allow us to <a href="#">support and scale-up the Company's U.S.-based managed care and related healthcare reimbursement efforts</a> , its clinical affairs efforts and its sales and marketing efforts. In addition, it will allow us to accelerate product development, amongst others, by conducting clinical studies to further support the clinical validity of the ConfirmMDx for Prostate Cancer test and tests in development for bladder cancer, and to finance general corporate purposes."	23/06/2015	27.675.000 €	6.150.000	4,50 €	230d
Overname NovioGendix in 09/2015 voor 8.8 mio €	18/09/2015	4.499.998 €	1.086.956	4,14 €	
these funds allow us to <a href="#">support and scale-up our U.S.-based managed care and related healthcare reimbursement efforts</a> , the sales and marketing efforts in the U.S. for ConfirmMDx and SelectMDx, and the sales and marketing and related commercialization efforts in Europe and the rest of the world for SelectMDx. In addition, it will allow us to accelerate the product development of the AssureMDx bladder cancer test, and to finance general corporate purposes."	03/11/2016	20.591.829 €	4.575.962	4,50 €	412d
	28/11/2017				